Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.1400 (0.78%) ($5.0900 - $5.2200) on Wed. Oct. 9, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.44% (three month average) | RSI | 23 | Latest Price | $5.1400(0.78%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -6.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.72% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-8%) UUP(-7%) IGOV(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.72% (StdDev 3.44%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-14.15(-375.29%) | Resistance Level | $5.76 | 5 Day Moving Average | $5.22(-1.53%) | 10 Day Moving Average | $5.3(-3.02%) | 20 Day Moving Average | $5.76(-10.76%) | To recent high | -37.5% | To recent low | 0.8% | Market Cap | $651m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |